This concorded with that reported by Abou Dalle et al. in the patients receiving chemotherapy.18 In contrast, we found that sorafenib maintenance post-transplantation might improve the survival of both FLT3-ITDhigh and FLT3-ITDlow AML patients, suggesting that sorafenib maintenance post-transplantation was required in FLT3-ITDlow AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.